SUMMARY Twenty nine patients who had had refractory supraventricular tachycardia were studied 4-36 (mean 16) months after transvenous fulguration of the atrioventricular junction. Twenty two had complete atrioventricular block, five partial atrioventricular block, and two had atrioventricular conduction via an accessory atrioventricular pathway. Though all patients were free of palpitation after the procedure, exertional dyspnoea had developed in 13 It is concluded that though transvenous fulguration is successful in controlling tachycardia it may reduce exercise capacity. Most patients remain in complete atrioventricular block after the procedure and, in contrast with the practice as described in early reports, would benefit from "physiological" pacing-though even with this mode exercise capacity is likely to be abnormal. 
responsive pacemakers demonstrated a significantly better but still impaired exercise capacity during "physiological" pacing as compared with their performance during constant rate pacing. In patients with complete atrioventricular block there was an increase in spontaneous ventricular rate during exercise in seven patients and in response to the Valsalva manoeuvre in eight patients. This suggests that the intrinsic ventricular pacemaker is influenced by autonomic nervous system activity in some patients.
It is concluded that though transvenous fulguration is successful in controlling tachycardia it may reduce exercise capacity. Most patients remain in complete atrioventricular block after the procedure and, in contrast with the practice as described in early reports, would benefit from "physiological" pacing-though even with this mode exercise capacity is likely to be abnormal.
Transvenous fulguration of atrioventricular conduction is a new technique used to treat recurrent supraventricular tachycardia in patients who do not respond adequately to, or who cannot tolerate, drug treatment and in whom antitachycardia pacing, where applicable, has proved ineffective.'l Little is known about its long term sequelae, though earlier reports have documented the rhythms produced.4 This study was prompted by the frequent complaints of breathlessness and reduced exercise tolerance from patients after transvenous fulguration of atrioventricular conduction. The aims were to assess exercise capacity and spontaneous heart rhythm, including response to exercise and the Valsalva manoeuvre, after atrioventricular fulguration.
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Patients and methods
We studied 29 patients (aged 19-67, 22 female). All patients had had frequent symptomatic supraventricular tachycardia and were refractory to or intolerant of antiarrhythmic drugs. Three patients had previously had antitachycardia pacemakers implanted that had not been consistently effective in controlling their symptoms. The arrhythmia that they had was atrioventricular reentrant tachycardia in eight patients, atrioventricular nodal reentrant tachycardia in eight, paroxysmal atrial fibrillation in seven (three had mitral valve disease), paroxysmal atrial tachycardia in two (one had mitral valve disease), and chronic atrial fibrillation/flutter in four (three had mitral valve disease). Though seven patients had mitral valve disease, the remaining 22 patients had no evidence of structural heart disease before transvenous atrioventricular fulguration.
Except for one patient transvenous atrioventricular fulguration was performed under general Table 2 shows the response of spontaneous heart rhythm to exercise. During exercise seven patients with complete atrioventricular block demonstrated an increase in intrinsic ventricular rate. The patient with atrial flutter showed enhancement of atrioventricular conduction on exercise, whereas two patients with first degree atrioventricular block before exercise developed an increase in the degree of block. One of the patients with accessory pathway conduction demonstrated rate dependent accessory pathway block on exercise. Table 3 shows the response of spontaneous heart rhythm to the Valsalva manoeuvre. Eight patients The most striking feature in these patients at review after transvenous atrioventricular fulguration was the frequency of exertional dyspnoea. Although all patients had been free of palpitation after the procedure, 13 patients had developed exertional dyspnoea and in two patients pre-existing dyspnoea has worsened. Two patients with mitral valve replacement and chronic atrial fibrillation who had had a rapid ventricular response (cases 27 and 28) had become less dyspnoeic after the procedure (table 5) . Before atrioventricular fulguration none of the 22 patients without evidence of structural heart disease complained of exertional dyspnoea. Although 13 complained of breathlessness after the procedure, this was not related to the type of pacemaker implanted; of those who complained of exertional dyspnoea, four had constant rate and nine had rate responsive pacemakers, and of those who remained free of dyspnoea, three had constant rate and six had rate responsive pacemakers. Eleven patients who complained of exertional dyspnoea and four who did not had complete atrioventricular block at the time of this study (table 5) .
The patients with exertional dyspnoea had a significantly shorter exercise time (p < 0-01) than the nine who remained symptom free when exercised in their usual pacing mode (fig 2) . Only four patients had exercise tests before undergoing transvenous atrioventricular fulguration. In these patients exercise capacity during treadmill testing before and after fulguration corresponded with the presence or absence of exertional dyspnoea.
Discussion
Most patients with recurrent supraventricular tachycardia respond satisfactorily to antiarrhythmic drug treatment. Surgical intervention, for example localised atrial excision6 ' and ablation of an accessory pathway,8 9 has been used for a few patients who were refractory to or intolerant of such treatment. For most patients, however, the only surgical treatment that is appropriate is ablation of the atrioventricular node and His bundle. has been attempted,"5 but this also produced similar changes in creatine kinase concentrations. The cause of the impaired exercise capacity and exertional dyspnoea in our patients remains uncertain but possibilities include the presence of or progression of coexisting heart disease, the implantation of constant rate pacemakers, pacemaker malfunction, myocardial or valvar damage produced at the time of fulguration, and impairment of the sinus node response to physiological stimuli.
During constant rate ventricular pacing the exercise capacity of patients without evidence of structural heart disease was reduced to 45% of that predicted. Most of these patients had reentrant tachycardia and almost certainly will have had otherwise normal hearts before atrioventricular fulguration. Atrial synchronised ventricular pacing improves exercise performance in most patients in complete heart block more than constant rate ventricular pacing."6 17 This improved work capacity is largely the result of the chronotropic response to exercise rather than the maintenance of the normal sequence of cardiac chamber activation. '8 19 Although 41 % of our patients had constant rate ventricular demand pacemakers, the exercise time of those with rate responsive systems was reduced to 63% of that predicted during "physiological" pacing. We also found that the development of exertional dyspnoea after atrioventricular fulguration was not related to the type of pacemaker (constant rate or rate responsive) implanted. The group of patients with dual chamber pacing systems who demonstrated a suboptimal rate response during exercise had as impressive an improvement in exercise capacity during "physiological" pacing as patients with optimal dual chamber function and with appropriate TX function. In addition, we found no evidence of sinus node dysfunction in patients with dual chamber systems. It is therefore difficult to attribute the impaired exercise capacity in our patients to coexisting heart disease or limitations of pacemaker function. One possible explanation is that transvenous atrioventricular fulguration impairs right or left ventricular function or both. Surawicz suggested that the lesion produced by atrioventricular fulguration could be appropriately characterised as the equivalent of a small septal infarction20 and it seems likely that there is more extensive damage than a mere interruption of the His bundle.
The results of our study suggest that rate responsive rather than constant rate pacemakers should be implanted after atrioventricular fulguration, in contrast with the practice described in an early report.2 Even with "physiological" pacing, however, exercise capacity is likely to be impaired. Therefore, we believe that young patients with atrioventricular or atrioventricular nodal reentrant tachycardia should only be treated with transvenous atrioventricular fulguration when frequent distressing symptoms persist despite medical treatment and, where appropriate, antitachycardia pacing.
